SCHEDULE: Fairmount Boosts ORUKA THERAPEUTICS Stake to 19.99%

Fairmount Funds Management LLC and affiliates increased their beneficial ownership in ORUKA THERAPEUTICS, INC. to 19.99% through a $5 million private placement.

Summary

• Fairmount Funds Management LLC and its affiliates now beneficially own 11,162,741 shares of ORUKA THERAPEUTICS, INC. Common Stock, representing 19.99% of the outstanding class.
• This ownership includes 3,705,262 shares of Common Stock, 1,253,572 shares from Pre-Funded Warrants, and 6,203,907 shares from Series B Preferred Stock conversion.
• Fairmount Healthcare Fund II L.P. purchased 333,340 shares of Common Stock in a private placement on September 17, 2025, for $15.00 per share, totaling $5,000,100.
• The private placement closed on September 19, 2025.
• ORUKA THERAPEUTICS, INC. entered into a Registration Rights Agreement, obligating it to file a registration statement by October 15, 2025, for the resale of shares purchased in the PIPE.

Sentiment

Score: 7

Explanation: The filing indicates a significant new investment by a major shareholder, which is generally positive for the company. The capital raise provides funding, and the investor's increased stake shows confidence. The registration rights agreement is also a positive for the investors. No explicit negative news is present.

Positives

• Significant investment of $5,000,100 by Fairmount Healthcare Fund II L.P. in ORUKA THERAPEUTICS, INC., demonstrating investor confidence.
• Successful closing of a private investment in public equity (PIPE) transaction, providing capital to the company.
• The Registration Rights Agreement provides a clear path for investors to resell their shares, potentially increasing liquidity for the PIPE participants.

Risks

• Beneficial ownership limitations on Pre-Funded Warrants (9.99%) and Series B Preferred Stock (19.99%, reducing to 9.99% under certain conditions) restrict immediate full conversion/exercise.
• The requirement for ORUKA THERAPEUTICS, INC. to file a registration statement for resale by October 15, 2025, could lead to future share price volatility if a large block of shares becomes available for sale.

Future Outlook

ORUKA THERAPEUTICS, INC. is required to prepare and file an initial registration statement with the SEC no later than October 15, 2025, to register for resale the shares of Common Stock purchased by investors in the private placement.

Industry Context

This transaction represents a significant capital infusion for ORUKA THERAPEUTICS, INC., a common occurrence in the biotechnology and pharmaceutical sectors where companies frequently raise funds through private placements to finance research, development, and operational activities. The involvement of a specialized healthcare fund like Fairmount Funds Management indicates continued investor confidence in the company's long-term prospects, despite the inherent risks of the industry.

Stakeholder Impact

• Shareholders: Potential dilution from the private placement, but also a vote of confidence from a major investor and a capital infusion for the company. Future share price volatility possible when registered shares become available for resale.
• Company (ORUKA THERAPEUTICS, INC.): Receives $5,000,100 in capital to support operations and strategic initiatives.

Next Steps

• ORUKA THERAPEUTICS, INC. is required to file an initial registration statement with the SEC by October 15, 2025, to register for resale the shares purchased in the PIPE.
• The Company will pay certain expenses related to the registration and indemnify securityholders against certain liabilities.

Key Dates

Recommendation

The filing details a significant capital raise of $5,000,100 through a private placement, with Fairmount Healthcare Fund II L.P. increasing its beneficial ownership to 19.99%. This indicates strong investor confidence and provides the company with additional working capital. However, as a Schedule 13D amendment, it primarily focuses on ownership changes rather than operational performance or future guidance. While the capital infusion is positive, the implied dilution from the PIPE and the future potential for resale of registered shares could introduce volatility. Without further information on the company's financial health, strategic progress, or market position, a 'hold' recommendation is prudent for a seasoned investor to observe how this capital is deployed and its impact on future performance.

Keywords

ORUKA THERAPEUTICS, Fairmount Funds Management, Schedule 13D, Private Placement, PIPE, Common Stock, Series B Preferred Stock, Pre-Funded Warrants, Beneficial Ownership, Registration Rights